Literature DB >> 33627620

PD-L1 regulates genomic stability via interaction with cohesin-SA1 in the nucleus.

Wen Zhang1, Jiali Jin1, Yanjin Wang1, Lan Fang1, Liu Min2, Xinbo Wang1, Lin Ding3, Linjun Weng3, Tan Xiao1, Tianhua Zhou2,4,5, Ping Wang6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33627620      PMCID： PMC7904913          DOI： 10.1038/s41392-021-00463-0

Source DB:  PubMed          Journal:  Signal Transduct Target Ther        ISSN： 2059-3635


× No keyword cloud information.
  5 in total

Review 1.  Cancer immunotherapy using checkpoint blockade.

Authors:  Antoni Ribas; Jedd D Wolchok
Journal:  Science       Date:  2018-03-22       Impact factor: 47.728

2.  Cohesin-SA1 deficiency drives aneuploidy and tumourigenesis in mice due to impaired replication of telomeres.

Authors:  Silvia Remeseiro; Ana Cuadrado; María Carretero; Paula Martínez; William C Drosopoulos; Marta Cañamero; Carl L Schildkraut; María A Blasco; Ana Losada
Journal:  EMBO J       Date:  2012-03-13       Impact factor: 11.598

3.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.

Authors:  Chih-Hao Chang; Jing Qiu; David O'Sullivan; Michael D Buck; Takuro Noguchi; Jonathan D Curtis; Qiongyu Chen; Mariel Gindin; Matthew M Gubin; Gerritje J W van der Windt; Elena Tonc; Robert D Schreiber; Edward J Pearce; Erika L Pearce
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

4.  Regulation of sister chromatid cohesion by nuclear PD-L1.

Authors:  Jia Yu; Bo Qin; Ann M Moyer; Somaira Nowsheen; Xinyi Tu; Haidong Dong; Judy C Boughey; Matthew P Goetz; Richard Weinshilboum; Zhenkun Lou; Liewei Wang
Journal:  Cell Res       Date:  2020-04-29       Impact factor: 25.617

5.  Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy.

Authors:  Yang Gao; Naoe Taira Nihira; Xia Bu; Chen Chu; Jinfang Zhang; Aleksandra Kolodziejczyk; Yizeng Fan; Ngai Ting Chan; Leina Ma; Jing Liu; Dong Wang; Xiaoming Dai; Huadong Liu; Masaya Ono; Akira Nakanishi; Hiroyuki Inuzuka; Brian J North; Yu-Han Huang; Samanta Sharma; Yan Geng; Wei Xu; X Shirley Liu; Lei Li; Yoshio Miki; Piotr Sicinski; Gordon J Freeman; Wenyi Wei
Journal:  Nat Cell Biol       Date:  2020-08-24       Impact factor: 28.213
  5 in total
  6 in total

Review 1.  Programmed death ligand 1 signals in cancer cells.

Authors:  Anand V R Kornepati; Ratna K Vadlamudi; Tyler J Curiel
Journal:  Nat Rev Cancer       Date:  2022-01-14       Impact factor: 60.716

2.  PD-L1 deficiency sensitizes tumor cells to DNA-PK inhibition and enhances cGAS-STING activation.

Authors:  Zhen Xue; Shuang Zheng; Dongli Linghu; Boning Liu; Yi Yang; Mei-Kuang Chen; Hua Huang; Jiaming Song; Hongyue Li; Jing Wang; Mien-Chie Hung; Diansheng Zhong; Linlin Sun
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

3.  Pharmacologic Tumor PDL1 Depletion with Cefepime or Ceftazidime Promotes DNA Damage and Sensitivity to DNA-Damaging Agents.

Authors:  Clare Murray; Eva Galvan; Carlos Ontiveros; Yilun Deng; Haiyan Bai; Alvaro Souto Padron; Kathryn Hinchee-Rodriguez; Myrna G Garcia; Anand Kornepati; Jose Conejo-Garcia; Tyler J Curiel
Journal:  Int J Mol Sci       Date:  2022-05-04       Impact factor: 6.208

Review 4.  Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy.

Authors:  Yiru Long; Xiaolu Yu; Runqiu Chen; Yongliang Tong; Likun Gong
Journal:  Front Immunol       Date:  2022-05-18       Impact factor: 8.786

Review 5.  The generation of PD-L1 and PD-L2 in cancer cells: From nuclear chromatin reorganization to extracellular presentation.

Authors:  Zhiwei Fan; Changyue Wu; Miaomiao Chen; Yongying Jiang; Yuanyuan Wu; Renfang Mao; Yihui Fan
Journal:  Acta Pharm Sin B       Date:  2021-09-16       Impact factor: 14.903

Review 6.  Cohesin Mutations in Cancer: Emerging Therapeutic Targets.

Authors:  Jisha Antony; Chue Vin Chin; Julia A Horsfield
Journal:  Int J Mol Sci       Date:  2021-06-24       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.